At the moment, there are 2 ongoing phase I/II clinical trials which try to evaluate the efficacy and safety of the intrathecal use of trastuzumab in patients with leptomeningeal carcinomatosis due to HER2-overexpressing breast cancer (NCT01373710; NCT01325207). This evidence concerns the gene ERBB2 and breast cancer.